Protein Drugs - Global Strategic Business Report

Description: This report analyzes the Global market for Protein Drugs in US$ Million by the following Drug Classes - Antibodies, Blood Products, Cytokines, Peptide Hormones, Vaccines, and Others (Including Peptide Antibiotics and Enzymes). Annual estimates and forecasts are provided for the period 2006 through 2015.


Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying

Contents: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW
- A Prelude
- Protein Drugs Are the Best Sellers
- Key Statistics:
  - Competitive Scenario
  - Intensifying Consolidation Activity
  - Impact of Recession: A Review
  - Impact of Recession on Drug Sales
  - Impact of Recession on R&D Activities
  - Not Recession, But Generic Competition Will Cause Sales Erosion
  - Patent Expiration
  - Impending Patent Expiry For Key Protein Drugs
  - Patent Expirations For Key Protein and Peptide Drugs in the Recent Past
  - Follow-on Biologics: An Opportunity in Adverse Conditions
  - Legal and Scientific Viability of Follow-on Protein Drugs
  - MAb: A Market Better Protected from Generic Competition
  - Approved Monoclonal Antibodies in the Market
  - Unmet Medical Needs in Emerging Markets Provides Fertile Environment
  - Key Market Trends & Issues: A Review
  - Continuous Fight Against Diseases: A Key Propeller for Growth
  - Population Aging Makes Rise Of Protein Drugs Inevitable
  - Ability to Address Wide Gamut of Diseases is Key to Success
  - Combination Biologics Can Offer New Treatment Possibilities
  - Shift Towards Humanized and Fully Human Antibodies
  - Biotechnology Gives a New Direction
  - Innovative Drug Delivery Methods: The Need of the Hour
- Increasing Demand for Protein A in Mab Manufacturing
- Rising Number of MAbs Under Clinical Trials
- Major Protein Drugs in Pipeline As of 2009
- Untapped Pharmacological Potential of GPCRs Ignites Interest
- Increased Reliance On Contract Manufacturing
- Reimbursement & Price Sensitivity Are Key Challenges
- Manufacturing Bottleneck
- High Costs Impede Penetration
- A Special Focus On Key Regional Markets
- United States
  - Market Overview
  - Biologicals: A Review
  - Biologicals: A Costly Preposition
  - Key Statistics:
    - China
    - Market Overview
    - China to Emerge As Biosimilar Major
    - Lack of Regulatory Framework
  - India
  - Market Overview
  - Openness in US Market Will Provide Opportunities

2. PRODUCT OVERVIEW
- An Introduction
- Structural Information
- Classification of Proteins
- Sources of Protein Drugs
- Types of Protein-Based Drugs
- Cytokines
- Clotting factors
- Hormones
- Monoclonal Antibodies (Mabs)
- Vaccines
- Different Types of Protein Drugs
- Applications
- Significance of Biotechnology in Protein-Based Drugs
- Hybridoma Cell Technology
- Recombinant DNA Technology
- Production of Protein Drugs through Transgenic Animals
- Disadvantages of Protein-based Drugs
- Immunogenicity of Protein-Based Drugs

3. PRODUCT INTRODUCTIONS/LAUNCHES
- Millipore Unveils AllostericProfiler™ Service
- BioDtech Introduces EndoPrep
- Amgen Introduces Vectibix
- Trevigen Introduces Mouse Monoclonal Antibody
- UCB Receives FDA Approval for Cimzia®
- PhyNexus Introduces PhyTip® ProPlus™ Columns

4. RECENT INDUSTRY ACTIVITY
- Novartis Vaccines Receives EC Approval for Menveo®
- Lonza Takes Over Algonomics
- Daicel Chemical Takes Over ChromTech
- Lonza to Manufacture Arzerra
- Maxygen and Astellas Complete Joint Venture Transaction
- Amgen Collaborates with GSK
- Nabi Biopharmaceuticals Inks Licensing Agreement with GSK
- Wyeth Pharmaceuticals and Ambrx Enter into Strategic Alliance
- OPKO Health and Academia Sinica Ink Exclusive License Agreement
- Seattle Life Sciences and ZymoGenetics Enter into Licensing Pact
- Roche and Covagen Enter into Collaboration
- Lonza to Manufacture Biologics for LFB and Medarex
- Protgen Establishes Protein Drug Innovation Center in Beijing
- National Cheng Kung University Inks MoU with ScinoPharm Taiwan
- Novo Nordisk and ZymoGenetics Signs Licensing Agreement
- Lipoxen Signs Collaboration Agreement with Pharmasyntez
- Debiopharm Group Inks License Agreement with Curis
- Bristol-Myers Squibb Acquires Medarex
- Sanofi Pasteur Signs Licensing Agreement with Syntiron
- Sanofi Pasteur Inks Strategic Agreement with ShanH
- Access Pharmaceuticals Acquires Somanta Pharmaceuticals
- IMUC Completes Molecular Antibody Technology Acquisiton
- Callista Merger Corporation Merges with Celldex Therapeutics
- Arana and Kyowa Hakko Sign Agreement to Jointly Develop ART 104
- Eusa Sells Antibody Research Business
- Dyax and Sanofi-Aventis Sign Agreements
- HGS Enters into Antibody Collaboration Agreement with Xencor
- Caprotec Bioanalytics and Merck Ink Collaboration Agreement
- Biomonitor Snaps Up Neutekbio
- GE Healthcare Takes Over MicroCal
- Arana Therapeutics Enters into Collaboration with Greenovation Biotech
- Bayer Healthcare Acquires Hemophilia Program Assets of Maxygen
- Sanofi Pasteur Holding Purchases Acambis
- GlaxoSmithKline Enters into Strategic Alliance with Archemix
- Talecris Biotherapeutics Inks License Agreement with Crucell
- Polyphor Signs Exclusive Licensing Agreement with Allergan
- Morphotek® Enters into Partnership with Pivotal BioSciences
- Raven Biotechnologies and CMC ICOS Biologics Ink an Agreement
- MacroGenics Purchases Raven Biotechnologies

5. FOCUS ON SELECT PLAYERS
- Abbott Laboratories, Inc. (US)
- Alexion Pharmaceuticals, Inc. (US)
- Amgen, Inc. (US)
- Biogen Idec (US)
- Bristol-Myers Squibb Company (US)
- Medarex, Inc. (US)
- Crucell N.V. (The Netherlands)
- Dendreon Corporation (US)
- Eli Lilly and Company (US)
- Emergent BioSolutions, Inc. (US)
- Genentech, Inc. (US)
- Johnson & Johnson (US)
- Centocor Ortho Biotech, Inc. (US)
- MedImmune, Inc. (US)
- Merck Serono S.A. (Switzerland)
- Schering-Plough Corporation (US)
- UCB Group (Belgium)
- Unigene Laboratories, Inc. (US)
- Vaccinogen, Inc. (US)

6. GLOBAL MARKET PERSPECTIVE
Table 4: World Recent Past, Current & Future Analysis for Protein Drugs by Geographic Region - US and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 5: World 10-Year Perspective for Protein Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2006, 2009, and 2015

Table 6: World Recent Past, Current and Future Analysis for Protein Drugs by Drug Type - Antibodies, Blood Products, Cytokines, Peptide Hormones, Vaccines, and Other Drugs
Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 7: World 10-Year Perspective for Protein Drugs by Drug Type - Percentage Breakdown of Dollar Sales for Antibodies, Blood Products, Cytokines, Peptide Hormones, Vaccines, and Other Drugs for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 56 (including Divisions/Subsidiaries - 58)

---------
Region/Country Players
---------
The United States 34  
Canada 2  
Japan 1  
Europe 18  
France 1  
Germany 3  
The United Kingdom 4  
Rest of Europe 10  
Asia-Pacific (Excluding Japan) 3

---------

Ordering:  
Order Online - http://www.researchandmarkets.com/reports/1382359/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,  
Guinness Centre,  
Taylors Lane,  
Dublin 8,  
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Protein Drugs - Global Strategic Business Report
Web Address: http://www.researchandmarkets.com/reports/1382359/
Office Code: SCD2ILQD

Product Formats
Please select the product formats and quantity you require:

Quantity

- Electronic (PDF) - Single User: USD 3950
- Hard Copy: USD 3950 + USD 57 Shipping/Handling
- Electronic (PDF) - 1 - 10 Users: USD 7505
- Electronic (PDF) - 1 - 15 Users: USD 9480
- Electronic (PDF) - 1 - 5 Users: USD 5530

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World